Neos Therapeutics

The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.  Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Worth area.

Neos Therapeutics Valuation Appears Low Should They Report Operating Profits In 2020

New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions

Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea

Improvements At Neos Therapeutics Aren't Reflected In The Share Price

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q3 2019 Results - Earnings Call Transcript

Cash burn dropped significantly in Q2 to only $2M.

Neos Therapeutics: A Small-Cap Turnaround

DALLAS and FORT WORTH, Texas, Sept.  25, 2019  (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products, today announced that Jerry McLaughlin, chief executive officer, will present a company overview at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 9:30 a.m. ET in New York, NY.

Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

DALLAS and FORT WORTH, Texas, Aug.  29, 2019  (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products, today announced that Jerry McLaughlin, Chief Executive Officer, will present a company overview at two upcoming conferences in September:

Neos Therapeutics to Present at Two Upcoming September Conferences

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2019 Results - Earnings Call Transcript

Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Neos Therapeutics (NEOS) Reports Q2 Loss, Misses Revenue Estimates

Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Neos Therapeutics Enters Oversold Territory

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q1 2019 Results - Earnings Call Transcript

Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates

Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neos Therapeutics (NEOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.

Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript

News for Neos Therapeutics Stock (NEOS)